Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer harboring EGFR mutations
暂无分享,去创建一个
Y. Nakanishi | K. Azuma | I. Okamoto | N. Tsuruta | Kentaro Tanaka | H. Ouchi | T. Harada | M. Takeshita | H. Wataya | K. Nosaki | S. Sakata | N. Nakagaki | E. Iwama | A. Fujii | K. Otsubo | R. Morinaga | Hiroshi Ouchi | Noriaki Nakagaki
[1] M. Ahn,et al. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.
[2] K. O'Byrne,et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] L. Sequist,et al. Acquired Resistance to First‐Line Afatinib and the Challenges of Prearranged Progression Biopsies , 2016, Journal of Thoracic Oncology.
[4] K. O'Byrne,et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. , 2016, The Lancet. Oncology.
[5] Yih-Leong Chang,et al. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients , 2016, Oncotarget.
[6] G. Getz,et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition , 2016, Nature Medicine.
[7] L. Sequist,et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. , 2015, The Lancet. Oncology.
[8] Chun-Ming Tsai,et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] William Pao,et al. Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers , 2013, Clinical Cancer Research.
[10] N. Socci,et al. Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling , 2011, Science Translational Medicine.
[11] J. Shih,et al. Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer , 2011, Clinical Cancer Research.
[12] S. Digumarthy,et al. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.
[13] A. Gemma,et al. F1000 highlights , 2010 .
[14] S. Toyooka,et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.
[15] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[16] M. Meyerson,et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models , 2008, Oncogene.
[17] K. Nishio,et al. Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients , 2022 .